Financhill
Back

Intellia Therapeutics Quote, Financials, Valuation and Earnings

Buy
53

NTLA
Intellia Therapeutics

Last Price:
62.84
Seasonality Move:
-1.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Intellia Therapeutics Price Quote

$62.84
-0.48 (-0.76%)
(Updated: August 8, 2022 at 3:10 PM ET)

Intellia Therapeutics Key Stats

Buy
53
Intellia Therapeutics (NTLA) is a Buy

Day range:
$60.93 - $65.25
52-week range:
$37.08 - $180.59
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
121.69
P/B ratio:
5.04%

Volume:
2M
Avg. volume:
1.4M
1-year change:
-61.66%
Market cap:
$4.8B
Revenue:
$33.1M
EPS:
$-5.03

How Much Does Intellia Therapeutics Make?

Is Intellia Therapeutics Growing As A Company?

  • What Is Intellia Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is 0.75%
  • What Is Intellia Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Intellia Therapeutics Stock Price Performance

What Is Intellia Therapeutics 52-Week High & Low?

Intellia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Intellia Therapeutics?

Is Intellia Therapeutics Cash Flow Positive?

  • What Is NTLA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$252.5M
  • What Is Intellia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $725.4M
  • What Is Intellia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$477.8M

Intellia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    NTLA return on invested capital is -44.49%
  • What Is Intellia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -35.29%
  • What Is NTLA Return On Equity?
    ROE is a measure of profitability and is -44.49%

Intellia Therapeutics Earnings Date & Stock Price

Intellia Therapeutics Competitors

Intellia Therapeutics Dividend Yield

Data Unavailable

Intellia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -2.43%
Revenue: 74.59% 47.7%

Analyst Recommendations

Buy Recommendations: 13
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 123.21
Upside from Last Price: 94.58%

Major Shareholders

  • How many NTLA shares are owned by institutional investors?
    93M NTLA shares are owned by institutional investors
  • How many NTLA shares are owned by insiders?
    2.1M NTLA shares are owned by insiders